J.P. Morgan Securities Engages in Derivative Transactions Amid Kangji Medical Holdings' Privatisation Process
Kangji Medical Holdings Ltd. has disclosed recent internal dealings involving J.P. Morgan Securities PLC, a Class (5) associate connected with the Offeror. On 5 September 2025, J.P. Morgan Securities PLC issued a derivative involving 23,500 reference securities, maturing on 10 February 2026, with a total amount of $207,427.45 paid. The same day, a closing out of a derivative contract involving 500 reference securities was conducted, maturing on 29 December 2025, with a total amount of $4,393.30 received. Additionally, J.P. Morgan Securities PLC issued further derivatives: one involving 351,000 reference securities maturing on 7 October 2026, and another involving 141,000 reference securities maturing on 3 November 2026, with total amounts of $3,101,252.78 and $1,242,766.81 paid, respectively. These dealings were made for the account of J.P. Morgan Securities PLC, which is ultimately owned by JPMorgan Chase & Co.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kangji Medical Holdings Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.